CN116529250A - 作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物 - Google Patents

作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物 Download PDF

Info

Publication number
CN116529250A
CN116529250A CN202180068383.4A CN202180068383A CN116529250A CN 116529250 A CN116529250 A CN 116529250A CN 202180068383 A CN202180068383 A CN 202180068383A CN 116529250 A CN116529250 A CN 116529250A
Authority
CN
China
Prior art keywords
cancer
alkyl
halogen
carcinoma
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068383.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·阿比尼尼
S·萨马达
B·奎拉
S·慕克吉
S·塔蒂亚萨赫布·戈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origine Oncology Co ltd
Original Assignee
Origine Oncology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origine Oncology Co ltd filed Critical Origine Oncology Co ltd
Publication of CN116529250A publication Critical patent/CN116529250A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180068383.4A 2020-08-04 2021-08-03 作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物 Pending CN116529250A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (1)

Publication Number Publication Date
CN116529250A true CN116529250A (zh) 2023-08-01

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068383.4A Pending CN116529250A (zh) 2020-08-04 2021-08-03 作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物

Country Status (11)

Country Link
US (1) US12570650B2 (https=)
EP (1) EP4192835A4 (https=)
JP (1) JP2023536504A (https=)
KR (1) KR20230061349A (https=)
CN (1) CN116529250A (https=)
AU (1) AU2021320052A1 (https=)
BR (1) BR112023002089A2 (https=)
CA (1) CA3188024A1 (https=)
IL (1) IL300387A (https=)
MX (1) MX2023001445A (https=)
WO (1) WO2022029617A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874808A (zh) * 2025-01-02 2025-04-25 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138114A1 (en) * 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
CN106456609A (zh) * 2014-06-20 2017-02-22 奥瑞基尼探索技术有限公司 作为irak4抑制剂的取代的吲唑化合物
WO2017030814A1 (en) * 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108137507A (zh) * 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
CN110366418A (zh) * 2017-02-28 2019-10-22 埃皮兹姆公司 抑制smarca2用于治疗癌症
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20190300521A1 (en) 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
AU2021205326A1 (en) * 2020-01-10 2022-07-21 Amgen Inc. SMARCA2-VHL degraders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456609A (zh) * 2014-06-20 2017-02-22 奥瑞基尼探索技术有限公司 作为irak4抑制剂的取代的吲唑化合物
WO2016138114A1 (en) * 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
CN108137507A (zh) * 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
WO2017030814A1 (en) * 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN110366418A (zh) * 2017-02-28 2019-10-22 埃皮兹姆公司 抑制smarca2用于治疗癌症
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874808A (zh) * 2025-01-02 2025-04-25 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Also Published As

Publication number Publication date
EP4192835A4 (en) 2024-08-21
US20240018134A1 (en) 2024-01-18
EP4192835A1 (en) 2023-06-14
JP2023536504A (ja) 2023-08-25
WO2022029617A1 (en) 2022-02-10
KR20230061349A (ko) 2023-05-08
MX2023001445A (es) 2023-05-08
BR112023002089A2 (pt) 2023-02-28
CA3188024A1 (en) 2022-02-10
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
IL300387A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
CN116529250A (zh) 作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物
US12371426B2 (en) Pyridazine derivatives as SMARCA2/4 degraders
CN109912655B (zh) Alk蛋白降解剂及其抗肿瘤应用
KR102785576B1 (ko) Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104370828A (zh) 用作raf激酶抑制剂的嘧啶衍生物
AU2021339298A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
JP2023513373A (ja) Ｐ２ｘ３修飾薬
WO2021201036A1 (ja) ヒドロキシピロリジン誘導体およびその医薬用途
JP2024502106A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
EP4034526A1 (en) Therapeutic compounds and methods of use thereof
CN120584103A (zh) 环状adp核糖水解酶的抑制剂、其使用方法
EA052684B1 (ru) 6​-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4
IL291418B2 (en) Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment
CN118871440A (zh) 3-取代的哒嗪化合物作为smarca2和/或smarca4降解剂
RU2845145C1 (ru) Соединения для подавления рака с мутацией egfr и их фармацевтическое применение
WO2025196686A1 (en) Fused bicyclic compounds as smarca2 and/or smarca4 degraders
KR20260001534A (ko) 신규한 이종이작용기 단백질 분해제 및 이의 용도
WO2025094065A1 (en) Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
WO2026036026A1 (en) (1h-indol-3-yl)(pyridin-2-yl)methanone derivatives as aryl hydrocarbon receptor (ahr) agonists for the treatment of inflammatory, autoimmune, metabolic or proliferative diseases
CN119233976A (zh) c-MYC mRNA翻译调节剂和其在癌症治疗中的用途
TW202606657A (zh) 新型異雙功能蛋白質降解劑以及包含其的藥物組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination